Stamford Pharmaceuticals announces the first patient on-study to be treated with ASN-002

Stamford Pharmaceuticals Inc and Ascend Biopharmaceuticals Ltd (its Australian affiliate) announces the first patient on-study to be treated with ASN-002 in combination with Erivedge® in a Phase 2a Study in BCNS and sporadic BCC subjects.

Press Release: 200813_First patient dosed_ASN-002